Key Trends in Nuclear Medicine and Radiopharmaceutical Therapy
EANM in Vienna provided a valuable opportunity to connect with colleagues, manufacturers and industry partners from across the nuclear medicine community.
Two topics stood out in particular: Terbium-161 (Tb-161) therapy and targeted alpha therapies, reflecting the continued interest in developing new approaches to targeted radionuclide therapy.
As research progresses, these areas are attracting increasing attention for their potential to expand treatment options and advance precision medicine.
Supporting innovation in nuclear medicine
At Light Medical, we work with specialist manufacturers to support nuclear medicine departments, radiopharmacies and research teams across the UK and Ireland.
Our portfolio includes products from IRE ELiT, Medi-Radiopharma, RadQual, ERS, Nuclear Shields and Raditech covering radiopharmaceuticals, generators, cold kits, radiation shielding and specialist equipment for nuclear medicine applications.
Attending EANM helps us stay connected with developments across the sector, strengthen relationships with our partners and identify opportunities to bring innovative products and solutions to the UK and Irish markets.
Looking ahead
The discussions in Vienna reinforced the importance of collaboration between manufacturers, researchers and clinical teams as the field continues to evolve.
We look forward to building on the conversations started at EANM and continuing to support the advancement of nuclear medicine.
To find out more about our products and manufacturing partners, explore the Light Medical website or get in touch with our team.
